73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
Study uncovers epigenetic source of resistance to targeted therapy in EGFR-mutant lung cancer

Study uncovers epigenetic source of resistance to targeted therapy in EGFR-mutant lung cancer

by Dana-Farber Cancer InstituteCredit:Cancer Cell(2023). DOI: 10.1016/j.ccell.2023.07.005When lung cancers driven by mutations in the EGFR gene become resistant to osimertinib or othe

Study uncovers epigenetic source of resistance to targeted therapy in EGFR-mutant lung cancer

by Dana-Farber Cancer InstituteCredit:Cancer Cell(2023). DOI: 10.1016/j.ccell.2023.07.005When lung cancers driven by mutations in the EGFR gene become resistant to osimertinib or othe
Bacteria subtype linked to growth in up to 50% of human colorectal cancers, researchers report

Bacteria subtype linked to growth in up to 50% of human colorectal cancers, researchers report

byFred Hutchinson Cancer CenterA microscope image shows a human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color. The bacterium is commonly found in people'

Bacteria subtype linked to growth in up to 50% of human colorectal cancers, researchers report

byFred Hutchinson Cancer CenterA microscope image shows a human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color. The bacterium is commonly found in people'
Experimental monoclonal antibodies can coax aggressive prostate and breast cancers into submission, finds research

Experimental monoclonal antibodies can coax aggressive prostate and breast cancers into submission, finds research

by Delthia Ricks , Medical XpressTherapeutic inhibition of VEGF binding to NRP2 activates anti-tumor immunity in a syngeneic model of prostate cancer that is resistant to aPD-L1 therapy. (A) Shown is

Experimental monoclonal antibodies can coax aggressive prostate and breast cancers into submission, finds research

by Delthia Ricks , Medical XpressTherapeutic inhibition of VEGF binding to NRP2 activates anti-tumor immunity in a syngeneic model of prostate cancer that is resistant to aPD-L1 therapy. (A) Shown is
What breast cancer risk assessments can tell you

What breast cancer risk assessments can tell you

by Justin Stebbing,The ConversationCredit: Unsplash/CC0 Public DomainActress Olivia Munn recently shared on social media that she had undergone a double mastectomy after being diagnosed with&nbs

What breast cancer risk assessments can tell you

by Justin Stebbing,The ConversationCredit: Unsplash/CC0 Public DomainActress Olivia Munn recently shared on social media that she had undergone a double mastectomy after being diagnosed with&nbs
Survival similar for Black, White prostate cancer patients in clinical trial setting

Survival similar for Black, White prostate cancer patients in clinical trial setting

by Elana GotkineFor metastatic castration-sensitive prostate cancer (mCSPC), overall survival and progression-free survival are similar for Black and White patients receiving first- or second-generati

Survival similar for Black, White prostate cancer patients in clinical trial setting

by Elana GotkineFor metastatic castration-sensitive prostate cancer (mCSPC), overall survival and progression-free survival are similar for Black and White patients receiving first- or second-generati
Study validates clinical utility of pan-tumor predictive biomarker for checkpoint inhibitor immunotherapy benefit

Study validates clinical utility of pan-tumor predictive biomarker for checkpoint inhibitor immunotherapy benefit

by Strata OncologyDevelopment of an integrative immunotherapy response score (IRS) model to stratify PD-(L)1 therapy benefit in patients with advanced solid tumors.aReal-world treatment an

Study validates clinical utility of pan-tumor predictive biomarker for checkpoint inhibitor immunotherapy benefit

by Strata OncologyDevelopment of an integrative immunotherapy response score (IRS) model to stratify PD-(L)1 therapy benefit in patients with advanced solid tumors.aReal-world treatment an
Screening age needs to be lowered to combat colorectal cancer 'epidemic,' say researchers

Screening age needs to be lowered to combat colorectal cancer 'epidemic,' say researchers

by University of OtagoCredit: Pixabay/CC0 Public DomainNew Zealand needs to lower the screening age for colorectal cancer if it wants to reverse the dramatic increase of people aged under 50 bein

Screening age needs to be lowered to combat colorectal cancer 'epidemic,' say researchers

by University of OtagoCredit: Pixabay/CC0 Public DomainNew Zealand needs to lower the screening age for colorectal cancer if it wants to reverse the dramatic increase of people aged under 50 bein
AI can predict the effectiveness of breast cancer chemotherapy

AI can predict the effectiveness of breast cancer chemotherapy

byUniversity of WaterlooCredit: Unsplash/CC0 Public DomainEngineers at the University of Waterloo have developed artificial intelligence (AI) technology to predict if women with breast cancer wo

AI can predict the effectiveness of breast cancer chemotherapy

byUniversity of WaterlooCredit: Unsplash/CC0 Public DomainEngineers at the University of Waterloo have developed artificial intelligence (AI) technology to predict if women with breast cancer wo
Metabolic reprogramming of tumor-associated macrophages

Metabolic reprogramming of tumor-associated macrophages

by Cactus CommunicationsThe article discusses the metabolic pathways involved in reprograming tumor-associated macrophages, immune cells which contribute to tumor growth. Credit: Yi Zhang from Zhengzh

Metabolic reprogramming of tumor-associated macrophages

by Cactus CommunicationsThe article discusses the metabolic pathways involved in reprograming tumor-associated macrophages, immune cells which contribute to tumor growth. Credit: Yi Zhang from Zhengzh
Genomic deletions explain why some types of melanoma resist targeted therapies

Genomic deletions explain why some types of melanoma resist targeted therapies

byCenter for Genomic RegulationCredit: CC0 Public DomainMelanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to allevia

Genomic deletions explain why some types of melanoma resist targeted therapies

byCenter for Genomic RegulationCredit: CC0 Public DomainMelanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to allevia
Experts boost activity of potential therapeutic target in triple-negative breast cancer

Experts boost activity of potential therapeutic target in triple-negative breast cancer

by Diana Yates,University of Illinois at Urbana-ChampaignCredit: Unsplash/CC0 Public DomainLess than 20% of diagnosed breast cancers are designated "triple-negative," lacking three typ

Experts boost activity of potential therapeutic target in triple-negative breast cancer

by Diana Yates,University of Illinois at Urbana-ChampaignCredit: Unsplash/CC0 Public DomainLess than 20% of diagnosed breast cancers are designated "triple-negative," lacking three typ
Some proteogenomic signatures linked to prostate cancer progression in patients with African and European ancestries

Some proteogenomic signatures linked to prostate cancer progression in patients with African and European ancestries

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainCertain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated wit

Some proteogenomic signatures linked to prostate cancer progression in patients with African and European ancestries

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainCertain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated wit